PEGYLATED INTERFERON-LAMBDA (PEGIFN-lambda) SHOWS SUPERIOR VIRAL RESPONSE WITH IMPROVED SAFETY AND TOLERABILITY VERSUS PEGIFN alpha-2A IN HCV PATIENTS (G1/2/3/4): EMERGE PHASE IIB THROUGH WEEK 12S. Zeuzem, S. Arora,B. Bacon,T. Box,M. Charlton,M. Diago,D. Dieterich,R. Esteban Mur,G. Everson, M. Fallon, P. Ferenci,R. Flisiak,J. George,R. Ghalib,N. Gitlin,A. Gladysz,S. Gordon,S. Greenbloom, T. Hassanein,I. Jacobson, L. Jeffers,K. Kowdley, E. Lawitz,S. Lee,B. Leggett, S. Lueth,D. Nelson,P. Pockros, M. Rodriguez-Torres,V. Rustgi,L. Serfaty,M. Sherman, M. Shiffman,R. Sola,M. Sulkowski, H. Vargas, J. Vierling,B. Yoffe, L. Ishak, D. Fontana,D. Xu, J. Lester,T. Gray, A. Horga, J. Hillson, E. Ramos, J. C. Lopez-Talavera,A. MuirJOURNAL OF HEPATOLOGY（2011）引用 37|浏览30暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
